Skip to main content

Table 1 Characteristics of patients with giant cell arteritis at diagnosis

From: Apolipoproteins and the risk of giant cell arteritis—a nested case–control study

Cases, n

100

Female sex, n (%)

81 (81)

Age at GCA diagnosis, mean, years

73.6 (SD 6.0) (range 56.9–85.8)

Time from screening to GCA diagnosis, median, years

12.0 (IQR 8.5–15.5) (range 0.3–19.1)

Positive biopsy, na

63 (63%)

Fulfilled ACR criteria, n

92 (92%)

Visual impairment at diagnosis, n (%)

41 (41%)

Large vessel involvement, n (%)

16 (16%)

ESR at time of diagnosis, meana

80.7 (SD 31.5)

CRP at time of diagnosis, mediana

89.0 (IQR 50.0–141.8)

Initial oral glucocorticosteroid dose, median, mgb

40 (IQR 20–60)

  1. Data available for: ESR 91 cases, CRP 72 cases, initial dose of glucocorticosteroids 96 cases
  2. GCA giant cell arteritis, ACR American College of Rheumatology, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SD standard deviation, IQR interquartile rate
  3. a93 cases underwent temporal artery biopsy, 83 had a representative biopsy according to the pathology report
  4. bPrednisolone in all cases. Nine patients received intravenous glucocorticosteroids prior to oral prednisolone